Nanotechnology Synergised Immunoengineering for Cancer

• Published in: European journal of pharmaceutics and biopharmaceutics 2021-03, Vol.163, p.72-101
• Main Authors: Chauhan, Deepak S., Dhasmana, Anupam, Laskar, Partha, Prasad, Rajendra, Jain, Nishant K., Srivastava, Rohit, Jaggi, Meena, Chauhan, Subhash C., Yallapu, Murali M.
• Format: Article
• Language: English
• ISSN: 0939-6411; 1873-3441
• DOI: 10.1016/j.ejpb.2021.03.010

Novel strategies modulating the immune system yielded enhanced anticancer responses and improved cancer survival. Nevertheless, the success rate of immunotherapy in cancer treatment has been below expectation(s) due to unpredictable efficacy and off-target effects from systemic dosing of immunotherapeutic. As a result, there is an unmet clinical need for improving conventional immunotherapy. Nanotechnology offers several new strategies, multimodality, and multiplex biological targeting advantage to overcome many of these challenges. These efforts enable programming the pharmacodynamics, pharmacokinetics, delivery of immunomodulatory agents/co-delivery of compounds to prime at the tumor sites for improved therapeutic benefits. This review provides an overview of the design and clinical principles of biomaterials driven nanotechnology and their potential use in personalized nanomedicines, vaccines, localized tumor modulation, and delivery strategies for cancer immunotherapy. In this review, we also summarize the latest highlights and recent advances in combinatorial therapies avail in the treatment of cold and complicated tumors. It also presents key steps and parameters implemented for clinical success. Finally, we analyse, discuss, and provide clinical perspectives on the integrated opportunities of nanotechnology and immunology to achieve synergistic and durable responses in cancer treatment.